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 Group B Streptococcus (GBS) can be found in the vaginal and genitourinary tract 
of females, as well as the genitourinary tract of males, where it behaves as a commensal 
organism. However, as an opportunistic pathogen, GBS has the capability to infect the 
immunocompromised, making it a major threat to neonates and fetuses. The pathogen can 
be passed from mother to baby either in utero or during birth. The capsule, which is a 
polysaccharide coating on the outside of the cell, is considered the most important 
virulence factor in GBS.  Expression of capsule plays a role in evasion of the host 
immune response to GBS infection. The presence of capsule on GBS depends on the 
CpsA protein, which is involved in the attachment of capsule to the cell wall. CpsA is a 
multi-functional protein containing an intracellular domain and two extracellular domains 
including the accessory and the LytR domains. Previous data demonstrates a small region 
within the accessory domain of CpsA that, when expressed separately, can have a 
negative effect on the amount of capsule on the cell. In this study, cell morphology 
analysis and capsule assays were used to determine the role of the accessory domain on 
CpsA function and capsule production. The data collected in this study suggest that the 
accessory domain is important in capsule expression, and without the accessory domain 
capsule expression cannot be complemented back to WT CpsA levels. In addition, this 
data shows that the intradomain region plays an important, but unknown role in CpsA 
function. Finally, for the first time, short chain morphologies were associated with 
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Group B Streptococcus (GBS) can be found in the vaginal and genitourinary tract 
of females, as well as the genitourinary tract of males, where it behaves as a commensal 
organism. However, as an opportunistic pathogen, GBS has the capability to infect the 
immunocompromised, making it a major threat to neonates and fetuses. The pathogen can 
be passed from mother to baby either in utero or during birth. The capsule, which is a 
polysaccharide coating on the outside of the cell, is considered the most important 
virulence factor of GBS [9].  Expression of capsule plays a role in evasion of the host 
immune response to GBS infection. The presence of capsule on GBS depends on the 
CpsA protein, which is involved in the attachment of capsule to the cell wall [9]. CpsA is 
a multifunctional protein containing an intracellular domain and two extracellular 
domains including the accessory and the LytR domains [8]. Previous data demonstrates a 
small region within the accessory domain of CpsA that, when expressed separately, can 
have a negative effect on the amount of capsule on the cell [17]. In this study, the 
deletion of the extracellular accessory domain of CpsA will help to determine the role of 
this domain on CpsA function and capsule production. Cell morphology analysis, capsule 
assays, and virulence studies will all be used to analyze results of a deletion of the 









 Streptococcus agalactiae, commonly referred to as Group B Streptococcus 
(GBS), is the leading cause of neonatal infection, premature birth, and stillbirth [20]. 
Research has suggested that GBS associated infections affect 2,000 live births per year in 
the United States [15]. GBS are Gram positive, beta-hemolytic, chain forming cocci that 
frequently colonizes the vaginal and genitourinary tract of females and the genitourinary 
tract of males [15,20]. They are normal colonizers of the vaginal microflora in 25% of 
healthy women, where it behaves as a commensal organism, leaving healthy individuals 
unimpacted [20]. However, as an opportunistic pathogen, GBS has the ability to infect 
the immunocompromised. The colonization of the vaginal and genitourinary tract of 
females makes GBS a serious threat to neonates and fetuses because the pathogen can be 
passed down from mother to baby, either in utero or during birth [17]. This pathway 
 
Figure 1. Ascending Group B Streptococcus (GBS) Infection. GBS can be 
passed down from mother to baby either in utero or during birth. Ascending 
infection during pregnancy involves bacterial colonization of the vagina, 
placental membranes, and amniotic cavity which increase the risk of fetal 
infection, injury, premature or stillbirths. (Vornhagen, et. al., Trends in 




allows GBS to move from the vagina, to the cervix and into the uterus, where the fetus 
can become infected (Figure 1) [17]. In utero, the fetus can aspirate contaminated vaginal 
fluid, allowing GBS to cross the blood brain barrier and cause meningitis [5].  
Worldwide, it is estimated that 18% of women are colonized, with approximately 
22 million pregnant women affected worldwide [18]. A recent meta-analysis performed 
in 2015 suggested that there were at least 409,000 maternal, fetal and infant cases of GBS 
infection annually [18]. While Africa makes up only 13% of the global population, it 
accounts for 54% of the worldwide estimated cases, and 65% of all GBS related fetal and 
infant deaths [18]. Early-onset infection is defined as occurring in less than 7 days after 
birth and late-onset infection is defined as occurring 7 days or later [20]. The same study 
performed in 2015 also estimated 205,000 infant cases with early-onset disease, and 
114,000 infant cases with late-onset disease [18]. Early-onset GBS infection is capable of 
causing premature and still births and is known to be the leading cause of neonatal 
meningitis and sepsis [17]. Other devastating effects of early-onset GBS infection are 
encephalopathy and immune impairments which can make it hard to fight other infections 
later in life [18]. Even individuals who overcome neonatal GBS infection can still have 
neurodevelopmental impairments later on in life [18]. Late onset GBS infection can also 
cause hearing and vision loss, learning disabilities, and seizures [18]. Some mothers and 
babies can recover from GBS infection, but with a mortality rate of 6%, even if they do 
recover there might be some impairments later on in life [18].  
The current treatment recommendations for infection prevention in neonates 
consists of late gestation screening and intrapartum antibiotic prophylaxis (IAP) [20]. 




infection. IAP is administered intravenously during labor in an effort to prevent the 
pathogen from infecting the newborn as it passes through the birth canal. Although IAP is 
effective in preventing neonatal infection, the rates of stillbirths and prematurity due to 
GBS has not decreased [20]. While these treatments are effective in reducing the 
incidence of GBS infection in the first week of life, they are not ideal because treatment 
with antibiotics in newborns depletes normal gut flora, which are important in the 
development of the immune system [4]. A recent longitudinal study compared the 
association of infant antibiotic exposure with childhood health outcomes [2]. This group 
found that exposure to antibiotics within the first two years of life was associated with an 
increased risk of childhood-onset asthma, allergic rhinitis, atopic dermatitis, celiac 
disease, overweight, obesity, and attention deficit hyperactivity disorder (ADHD) [1]. 
Penicillin was one of the most prescribed antibiotic classes in this study and is also the 
standard antibiotic used for IAP in pregnant women, showing the devastating effects of 
infant antibiotic use [2]. Recent research also suggests that intrapartum antibiotic 
exposure may increase risk of sepsis from other bacteria colonizing the genitourinary 
tract [3]. IAP use also affects the mother, potentially increasing the risk of antibiotic 
resistance and adverse maternal affects such as allergic reactions [3]. While the use of 
IAP is not ideal for mother or baby, its use has doubled in the past 30 years, since no 
other ideal treatment options have emerged [3]. Late gestational screening and IAP are 







Virulence Factors of GBS 
 GBS encodes many virulence factors that aid in its pathogenicity. Some virulence 
factors that promote immune evasion include superoxide dismutase, C5a peptidase, serine 
protease, and penicillin-binding proteins [11]. Two major virulence factors that play an 
important role in GBS dissemination into host cells are pore-forming toxins and sialic 
acid containing capsular polysaccharide [11]. Genomic sequencing data has suggested 
80% similarity among GBS strains, showing the high conservation of virulence factors 
[11]. 
 GBS encodes superoxide dismutase to resist reactive oxygen species from the 
host [11]. These enzymes convert superoxide anions to molecular oxygen and peroxide, 
which can then be metabolized by other enzymes like catalases or peroxidases [11]. In 
order to cleave and inactivate human complement component C5a, GBS encodes a C5a 
peptidase [11]. This aids in immune evasion because C5a plays a role in neutrophil 
recruitment [11]. Serine proteases cleave the extracellular matrix protein fibrinogen to 
fibrin like products, ultimately preventing pathogen recognition and phagocytic uptake of 
GBS [11]. Penicillin binding proteins are utilized by bacteria to synthesize peptidoglycan 
and resist phagocytosis [11, 20].  
Pore-forming toxins are common in many pathogenic bacteria because they allow 
the entry of the pathogen into host cells [11]. GBS encodes at least two pore-forming 
toxins, which are denoted β-hemolysin/cytolysin (β-H/C) and Christie Atkins Munch 
Peterson (CAMP) factor [11]. β-H/C promotes GBS infection by allowing for the 
invasion of host epithelial and endothelial cells of the lung and blood brain barrier [11]. 




inflammatory responses that can cause neurological damage [11]. On the other hand, 
CAMP factor is a secreted protein which is known to oligomerize and form small pores 
on susceptible target host cells [11]. It is hypothesized that these pore-forming toxins 
have compensatory mechanisms in the absence of one of them, which aids in causing a 
systemic infection in the host [11].  
While the virulence factors described above are all important in immune evasion, 
sialic acid rich capsular polysaccharide is understood to be the most important virulence 
factor of GBS infection [8].  The capsule of GBS contains sialic acid residues that mimic 
host cells (Figure 2). Sialic acids are nine carbon sugars that are also typically found on 
glycans of host cells [11]. Utilizing this molecular mimicry, the pathogen evades the 
immune system and the host fails to recognize GBS as a foreign substance [11]. As a 
result of this evasion, the capsule also prevents complement factor C3b from being 
activated and consequently prevents phagocytosis of the pathogen [11].  
 
Capsule in Streptococcal Species 
GBS is not the only Streptococcal species that requires capsule for survival in 
host epithelial cells. The capsule operon is highly conserved among Streptococcal species 
and other Gram-positive organisms [7]. The first gene on this locus is the cpsA gene, 
which encodes one of the transcriptional regulators of the capsule operon, the CpsA 
protein [7]. The CpsA protein is understood to directly aid in the production of capsule 
and virulence of the bacteria [8]. This protein has been the main focus of much of the 




the focus of the GBS research being performed in the Neely lab at the University of 
Maine.  
In Streptococcus 
pneumoniae and Streptococcus 
suis, the presence of capsule 
had a significant effect on the 
minimal bactericidal activity of 
many cell wall reactive agents 
[6]. The first four genes of the 
capsule operon in S. iniae and 
GBS have 70% amino acid 
similarity, suggesting that CpsA 
is highly conserved as a control mechanism for virulence in Streptococcal species [8]. 
This observation suggests that capsule is mediated by the CpsA protein [6]. Further 
research demonstrates that the purified CpsA protein specifically binds to the capsule 
promoter region of DNA [8].  
 
 
Figure 2. Electron micrograph of the capsular polysaccharide 
of Group B Streptococcus. (F.D. Xia, et. al. (2015). Microbes 





Streptococcus iniae, a zoonotic pathogen that is able to infect both animals and 
humans, also contains the CpsA protein. Previous research of S. iniae infection in 
zebrafish showed that CpsA mutants were more susceptible to phagocytosis than WT, 
confirming that CpsA plays a role in capsule production and thus virulence (Figure 3) [9]. 
In this study, small doses of WT S. iniae were injected into the dorsal muscle of adult 
zebrafish. This induced infection resulted in a high mortality rate and large bacterial 
burden [9]. Injection of CpsA mutant S. iniae reduced lethality, however, and there was 
no increase in bacterial burden, suggesting that the mutated CpsA protein decreases the 
virulence of GBS [9]. This research summarizes that bacterium-phagocyte interaction are 
different between the WT and CpsA mutant, suggesting that WT is pathogenic, and the 
CpsA mutant is non-pathogenic, confirming its clinical relevance in the treatment of GBS 
infection [9]. The capsule of S. iniae is closely related to GBS, suggesting that these data 
may be generalized to include GBS [9]. 
Figure 3. Percent zebrafish survival after 7 days post injection. Media was used as a negative 
control and 100% of zebrafish survived after 7 days post injection. In the CpsA mutant GBS and S. 
iniae, 40% of zebrafish died after 7 days post injection. In the GBS and S. iniae WT, 100% of 
zebrafish died after 7 days post injection. This data indicates that the mutant CpsA strains of 
Streptococcal species are less virulent than WT strains, suggesting that CpsA is an important 





CpsA Protein of GBS 
CpsA has an intracellular N-terminal domain, three transmembrane domains, and 
an extracellular domain, including the C-terminal domain (Figure 4). The extracellular 
portion of the protein is broken into two domains, the accessory and LytR domains [9]. 
These two domains are connected by an intradomain region of uncharacterized structure 
and function. The extracellular domains of CpsA are known to fold separately and have 
separate functions (Figure 5) [9]. While the CpsA protein is a member of the 
LytR_CpsA_Psr protein family, it has several differences compared to other members of 
the family [8]. The CpsA protein is the only member of its family that possesses an 
extracellular accessory domain, and it also has three transmembrane domains instead of 
one [12].  
 
Intracellular CpsA Domain 
The intracellular N-terminal domain of CpsA is a small, cytoplasmic region that is 
highly conserved in both GBS and other Gram-positive organisms [8]. While the 
Figure 4. CpsA protein topology embedded within the cell membrane, including the N 
terminus, three transmembrane domains, two extracellular domains, and C terminus. (No 





complete function of this domain is not understood, research suggests that it does contain 
a DNA binding region [8]. The high density of positively charged amino acids allows this 
region to bind its own promoter, attracting the negatively charged backbone of DNA to 
bind [8].  
Previous research on the intracellular domain of the CpsA proteins of S. 
pneumoniae and GBS suggests that there is a leucine zipper domain which extends into 
the transmembrane region and is commonly associated with DNA binding through 
dimerization [6]. Regardless of the similarity between the intracellular domains of GBS 
and S. pneumoniae, no data has supported similarity between these regions of S. iniae and 
GBS, suggesting the need for further research of this leucine zipper motif [6]. Although 
there are genomic differences between this region in Streptococcal species, the GBS and 
S. iniae CpsA proteins do bind DNA in vitro, however, the mechanism is unknown [7].  
 
Extracellular Domains 
The focus of this research is understanding how the accessory domain of CpsA 
affects capsule production and expression. It is important to understand the structure of 
the accessory and LytR domains of CpsA and how they function extracellularly because 
CpsA is the only protein in its family that carries the accessory domain. As mentioned 
previously, these domains fold separately and have separate functions (Figure 5) [12]. 




LytR domain [12]. This region shows little structural homology to any other protein, only 
having 11% sequence identity with an uncharacterized peptide binding protein [12]. 
 
GBS CpsA is unique in that it is the only member of the protein family which 
possesses an extracellular accessory domain which has no homology to any other protein 
domains [17]. While no previous research has deleted the accessory domain, one study 
suggested that, in the absence of the LytR domain, the extracellular accessory domain 
decreases capsule production and cell wall integrity [17]. This mutation causes a 
dominant negative effect, where the mutation interferes with the wild type form of the 
protein [17]. A dominant negative effect occurs extracellularly when the accessory 
domain interferes with normal mechanisms of cell wall integrity and capsule production 
[17]. It has been hypothesized that specific conformations of CpsA might allow the 
accessory domain to negatively impact CpsA binding interactions, thus decreasing 
capsule production and cell wall synthesis [17]. Overall, this dominant negative effect 
Figure 5. Crystal structure of the extracellular domains of CpsA in 
S. pneumoniae. D1 represents the accessory domain and D2 
represents the LytR domain, which are connected by an 






indicates that the accessory domain plays an important role in virulence, whether it is 
capsule dysregulation or cell wall instability remains unknown [17]. The production of a 
dominant negative effect is of clinical importance in the treatment of GBS infection. 
Much of the function and mechanisms of the accessory domain are not understood, 
suggesting the need for further research to determine its implications in capsule 
production and GBS virulence.  
Previous research performed on the extracellular domains of CpsA focused on the 
LytR domain, leaving the function and mechanism of the accessory domain largely 
unknown. Much of this research was also studied in Streptococcal species other than 
GBS, as well, making the specific mechanisms of these domains in GBS unknown as 
well. Previous research on the LytR domain, however, suggests that it aids in the 
attachment of cell wall carbohydrates, capsule, and teichoic acids to the cell wall [17]. 
Carbohydrate precursors are first made on the inner leaflet of the bacterial membrane, 
then the outer membrane, where it is hypothesized that the LytR domain acts as a ligase, 










Previous research performed in the Neely lab suggests that the accessory domain 
has some function independent of the LytR domain (Figure 6). In this study, a buoyant 
density assay was performed in order to determine the buoyancy of cells based on a sugar 
gradient which is directly correlated to capsule expression. Figure 6 displays the 
measurements of capsule expressed by both full and truncated versions of GBS CpsA. 
The first four bars were used as controls and the last two bars were the experimental 
samples. The first sample shows WT GBS and an empty vector, displaying the standard 
Figure 6. A) Buoyant density measurements of capsule expressed by full and truncated GBS CpsA 
proteins. B) Full length GBS CpsA protein. C) ∆LytR truncated GBS CpsA protein. D) 





amount of capsule expressed. The second bar shows the deletion of CpsA with an empty 
vector, showing how much less capsule is produced when CpsA is deleted from GBS. 
When compared to the WT + vector sample, approximately half as much capsule is 
expressed when CpsA is deleted. The third bar displays the deletion of CpsA with the full 
CpsA protein expressed on a plasmid, showing how much capsule production can be 
complemented back with CpsA from a plasmid. When compared to the WT + vector 
sample, almost all of the capsule is complemented back with CpsA from a plasmid. The 
fourth bar displays WT GBS and the deletion of the LytR domain expressed from a 
plasmid and shows the effect of capsule production if the extracellular domain is 
truncated. When compared to the WT + vector sample, less capsule is expressed, 
indicated the dominant negative effect of this mutation, because the WT CpsA is still 
present on the chromosome. Therefore, the presence of the truncated CpsA can override 
the function of the WT full length protein. The fifth bar displays the deletion of the first 
and second transmembrane domain, intracellular domains, and the LytR domain, leaving 
just the third transmembrane domain and the accessory domain remaining and expressed 
from a plasmid in the WT strain (WT CpsA still present). This data shows that when 
DNA binding domains were removed, capsule production was approximately the same as 
the WT + ∆LytR capsule production, supporting the hypothesis that inhibition of capsule 
production is due to the extracellular domain, not the intracellular domains. Finally, the 
sixth bar shows the CpsA deletion mutant GBS with the truncated CpsA (accessory 
domain and third transmembrane domain) expressed from a plasmid. When compared to 
the ∆CpsA + CpsA data (third bar), the data suggests that this truncated version of CpsA 




together suggests that the accessory domain functions independently of the LytR and 
intracellular domains, inhibiting capsule production in some way.  
 
Research Goal 
The polysaccharide capsule of GBS is suggested to be the most important 
virulence factor in GBS infection [8]. The sugar coating the outside of the cell wall is 
decorated in sialic acid residues which mimic host cells, aiding in immune evasion [21]. 
Because of this molecular mimicry, GBS is able to target and colonize different parts of 
the body, including the spleen, heart, and brain, making it the leading cause of neonatal 
meningitis and sepsis [20]. It is of clinical relevance to understand the mechanisms of 
dissemination used by GBS and other human pathogens to survive in various 
environments, such as the epithelium of the vaginal tract [7]. Because of the function of 
capsule, it is important to understand its interactions in the human body in order to further 
antimicrobial therapy [3].  
The goal of this research study is to alter part of the CpsA protein of GBS in order 
to determine its function. The region of interest is the accessory domain of the CpsA 
protein. The CpsA protein belongs to the LytR-CpsA-Psr protein family, which is known 
to act as a ligase, attaching the capsule to the cell wall. The CpsA protein is the only 
protein in this family that has an extracellular accessory domain, but the specific function 
of the accessory domain remains unknown. This research study aims at determining the 
function of the accessory domain of the CpsA protein through its deletion and to 











The plasmid pLZ12-rofA-pro (strain #12E34) was digested with BamHI and 
incubated at 37ºC for 15 minutes. Then, the plasmid was digested again with PstI and 
incubated at 37ºC for 30 minutes and was then moved to 80ºC for 5 minutes to inactivate 
the restriction enzymes. The digested plasmid was separated on a 0.8% agarose gel to 
check for a band at 4500 bp. GeneJet Gel Extraction Kit (ThermoFisher) was used to 
isolate the plasmid from the gel.  
 
Polymerase Chain Reaction (PCR) 
Streptococcus agalactiae genomic DNA was used as a template to amplify the 
cpsA gene region. A high-fidelity DNA polymerase, Q5 (New England Biolabs), was 
Figure 7. plZ12-rofA-pro plasmid map. Mutant strains of CpsA 
were inserted into the plasmid using BamHI and PstI restriction 
sites. Chloramphenicol was used as a selectable marker for positive 
transformants. repR is an initiator protein which allows the plasmid 






used and the primers were specific to each reaction. The long fragment (Reaction 1, 
Figure 8) used primers 5’ GBS-CpsA-RBS-BamHI and 3’ GBS-CpsA-∆AD (#1740, 
#1903). The short fragment (Reaction 2, Figure 8) used primers 3’ GBS-CpsA-full-PstI 
and 5’ GBS-CpsA-∆AD (#1672, #1902). PCR was performed using a Thermocycler at an 
annealing temperature of 68ºC. Both reactions were separated on 0.8% agarose gel to 
confirm fragments of ~300bp and ~1178bp. Both reactions were gel purified using the 
GeneJet Gel Extraction Kit (ThermoFisher).  
 
PCR Splice Overlap Extension (SOE) 
The two PCR fragments created were used as a template to SOE the fragments 
together, forming a full-sized fragment of ~1000 bp. Q5 DNA Polymerase (New England 
Biolabs) and primers #1672 and #1740 were used at an annealing temperature of 65ºC. 
The reaction was separated on a 0.8% agarose gel to confirm the final full-sized 
fragment. The full-sized fragment was gel purified using the GeneJet Gel Extraction Kit 
(ThermoFisher), followed by digestion with BamHI and PstI. 
 
Ligation 
The digested PCR SOEing fragment was inserted into the plasmid using T4 DNA 
ligase (New England Biolabs). The reaction was incubated at 37ºC for 30 minutes. 









Transformation into E. coli 
The ligation reaction was mixed with electro-competent cells and transferred to 
cold electroporation cuvettes (Figure 9). The cells were electroporated with a Gene Pulser 
(BioRad), with settings at 25 µF, 2.5 kV, and 200 Ω. Immediately after electroporation, 
the cells were transferred to SOC medium and incubated at 37ºC for 90 minutes with 
continual shaking. Cells were then plated onto Luria-Bertani (LB) agar plates 
supplemented with chloramphenicol (cam) at a final concentration of 15 µg/mL final 
Figure 8. PCR SOEing model. The full protein contains the three transmembrane domains and 
both extracellular domains, the accessory and LytR domains. The truncated protein shows the 
deletion of the accessory domain, containing the three transmembrane domains and the LytR 
domain. Reactions 1 and 2 were used to delete the accessory domain of CpsA, and reaction 3 





concentration. Plates were incubated at 37ºC overnight. Several transformants were 
purified on fresh LB-Cam plates. PCR of several purified transformants was performed to 
confirm the proper insertion of the PCR SOEing fragment.  
 
Colony PCR 
 To confirm the proper insertion of the cpsA gene on the plasmid in E. coli, colony 
PCR was performed. The outside primers (#1672, #1740) were used to amplify the final 
fragment in the plasmid and then visualized by electrophoresis.   
 
Plasmid Isolation 
An overnight culture of a confirmed positive transformant was grown at 37ºC in a 
shaking incubator overnight in a 250 mL Erlenmeyer flask with 100 mL of LB broth 
supplemented with 15 µg/mL chloramphenicol. The next day, a PureLink HiPure Plasmid 






Filter DNA Purification Kit (Invitrogen) was used to purify plasmid DNA. Isopropanol 
and ethanol precipitation were performed, and a Nanodrop (ThermoFisher) was used to 
determine the concentration of the isolated DNA. The plasmid insert was sequenced to 
confirm that the construct was correct and that no mutations were created by PCR.  
 
Transformation into GBS 
GBS515 cultures were grown statically in THY B (Todd-Hewitt-Yeast Broth) 
supplemented with 80 mM glycine overnight at 37ºC in a shaking incubator. A 1:20 
dilution (1.25 mL) of the culture in 25 mL of THY B supplemented with 80 mM glycine 
the following day. The subculture was grown to an OD600 of 0.4 and harvested by 
centrifugation. The cells were washed and resuspended with 10% glycerol. Cells were 
then transferred to a cold electroporation cuvette. The isolated plasmid was added to the 
cold cuvette. The cells were electroporated with a Gene Pulser (BioRad), with settings at 
25	µF, 2.0 kV, and 400 Ω (Figure 10). Immediately after electroporation, cells were 
transferred to THY B medium and incubated at 37ºC for 90 minutes with continual 
shaking. Cells were then plated on THY B supplemented with chloramphenicol at a final 
concentration of 3 µg/mL. Cells were transformed into both WT and ∆cpsA GBS strains. 






Enzyme-linked immunosorbent assay (ELISA) 
Strains were grown in THY B-Cam3 broth at 37ºC overnight. Cultures were 
normalized to an OD600 of 0.75, pelleted, and washed three times with Tris-buffered 
saline + Tween (TBST). Primary antibody (rabbit anti-Serotype 1a GBS) was diluted to 
1:20,000. Secondary antibody (secondary goat, anti-rabbit IgG conjugated to alkaline 
phosphatase [AP]) was diluted to 1:5,000. Secondary antibody was pre-absorbed to 
prevent nonspecific binding using both ∆cpsA and WT GBS strains. Cells were incubated 
with 1 µL primary antibody at 4ºC for 1 hour with rocking before being washed three 
more times with TBST. Cells were then incubated with secondary antibody for 1 hour 
with rocking at 4ºC before being washed three more times with TBST. Cells were 
resuspended in TBST and transferred to a 96-well plate. Alkaline phosphatase activity 
was measured after a 1 hour incubation in the dark at 37ºC after addition of p-nitrophenyl 
phosphate substrate (Sigma) (Figure 11). OD405 and OD600 were used to calculate AP 
activity and cell growth, respectively. Each sample was done in triplicate at a 1:1, 1:2, 
Figure 10. Electrotransformation into GBS. The plZ12-rofA-pro plasmid was isolated from E. coli 





and 1:4 dilution. Each experiment was repeated three times. Alkaline phosphatase (AP) 
units were calculated using the following equation: 
𝐴𝑃	𝑈𝑛𝑖𝑡𝑠 =
𝑂𝐷!"#
𝑉𝑜𝑙 ∗ 𝑇 ∗ 𝑂𝐷$""
∗ 1000 
Vol = culture volume in well 
T = time of incubation with substrate 
 
Chain Length Analysis 
Overnight cultures of all strains were grown statically at 37ºC in THY B medium. 
Using 7 µL of the overnight culture, wet mount slides were made and visualized with a 
Zeiss Axioskop compound microscope. Multiple images of each strain were documented, 




Figure 11. Enzyme-linked immunosorbent assay 
(ELISA) can be used to measure the amount of 
capsule on the cell. A) A primary antibody to the 
capsule is recognized by a secondary antibody, 
conjugated to alkaline phosphatase (AP). B) Plate 
of ELISA reactions. The wild type GBS will 
express a yellow color due to the presence of 
capsule. The ∆cpsA GBS will show a pale-yellow 
color due to the amount of capsule. The result of 
∆AccessoryDomainCpsA GBS is unknown. (No 






Cell Aggregation Assay 
Overnight cultures of all strains were grown statically in clear, round bottom 
tubes at 37ºC in THY B medium with antibiotics. Following 48 hours of growth, the 

























Plasmid Construction  
 Plasmid construction was 
carried out as described in the 
materials and methods. Following 
plasmid construction, PCR was 
performed to create truncated 
versions of the fragment of sizes 
~3000 bp and ~1178 bp. After gel 
purification, PCR SOEing was 
performed to form a truncated 
fragment of ~1000 bp. The full-
length fragment was then digested 
and ligated before transforming into 
E. coli. Positive transformants were 
selected via colony PCR and DNA 
was isolated and used to transform into GBS after sequencing to confirm the correct 
mutation (Figure 12). 
 In this study, six different strains of GBS were constructed in order to compare 
the effects of a deletion of the accessory domain, both with and without the intradomain 
region remaining (Figures 13,14). In strains that have WT background, WT CpsA was on 
the chromosome and expressed in addition to what was expressed on the plasmid (Figure 
14). In strains that have ∆CpsA background, the only CpsA expressed was from the 
Figure 12. Gel electrophoresis of colony PCR shows 
positive colonies with a band at ~1470 bp. Positive 
colonies were those that included a successful 
deletion of the accessory domain, resulting in a 





plasmid (Figure 14). Both the WT GBS and ∆CpsA GBS expressed either an empty 
vector, or a plasmid expressing WT CpsA, ∆Acc+ CpsA, or ∆Acc- CpsA (Figures 14-
17). The ∆Acc+ CpsA included the intradomain region, while the ∆Acc- CpsA did not 






Figure 13. Comparison of WT CpsA to the truncated versions used in this study. A) Full length 
CpsA protein. B) ∆Acc+ CpsA, where the three transmembrane domains, intradomain region, and 
LytR domain remain, with a deletion of the accessory domain. C) ∆Acc- CpsA, where the three 
transmembrane domains and LytR domain remain, with the deletion of the accessory domain and 








Figure 14. Construction of all 6 strains used in this study. WT GBS and ∆CpsA GBS expressing an 




































Chain Length Analysis 
 Previous research examined the relationship between chain length and cell wall 
integrity [7]. The data shows that WT strains express shorter chains of cocci, 2-6 cocci per 
chain, and ∆CpsA strains express much longer chains of cocci, up to 20 cocci per chain 
[7]. Long chain morphologies have been associated with less capsule expression [7]. In this 
study, researchers treated all GBS strains with a subinhibitory amount of lysozyme and 
compared the chain lengths between the treated and untreated strains [7]. Lysozyme has 
enzymatic activity that cleaves specific residues of the peptidoglycan cell wall. 
Specifically, it has muramidase activity which cleaves the N-acetyl-D-glucosamine 
residues of the peptidoglycan cell wall [7]. After growing in the presence of lysozyme, all 
cells existed as either diplococci or single cocci in both the WT and ∆CpsA strains [7]. 
This data suggests that CpsA dependent changes to the cell wall may be responsible for the 
observed chain length variances [7].  
To determine the differences in morphology between the different GBS strains 
examined in this study, 10 images of each strain were visualized and documented using 
light microscopy at 1000X magnification using a Zeiss Axioskop compound microscope 
(Figure 18). The number of cocci in each GBS chain was counted and recorded. The 
average cocci per chain was determined for each GBS strain (Table 1).  Overall, the 
∆CpsA mutant strains had longer chain lengths relative to the WT strains. When 
compared to the WT-vector, ∆CpsA-vector expressed slightly longer chains. The average 
chain length in the WT-vector strain was 1.784 cocci, while the average chain length in 
the ∆CpsA-vector strain was 3.26 cocci (Table 1). The ∆CpsA-vector strain also showed 




When compared to the WT-∆Acc+ strain, the ∆CpsA-∆Acc+ strain expressed much 
greater variation in chain length (Figures 21, 22). The average chain length of the WT-
∆Acc+ strain was 1.897 cocci per chain, while the average length of the ∆CpsA-∆Acc+ 
strain was 6.35 cocci (Table 1). The majority of the chains in the WT-∆Acc+ strain were 
between 1-4 cocci per chain, but the ∆CpsA-∆Acc+ strain expressed much greater 
variation in chain length, with a range from 1 cocci per chain to 23 cocci per chain 
(Figures 21, 22, Table 1). When compared to the WT-∆Acc- strain, the ∆CpsA-∆Acc- 
strain expressed longer chain lengths (Figures 23, 24). The average chain length for the 
WT-∆Acc- strain was 1.843 cocci, while the average chain length for the ∆CpsA-∆Acc- 
strain was 4.059 cocci (Table 1). The ∆CpsA-∆Acc- strain also expressed more 
distribution in chain length, with a range from one cocci per chain to 23 cocci per chain. 
The majority of the chains in the WT-∆Acc- strain were between 1-4 cocci per chain 
(Figure 23). When each strain was compared to one another, the WT-V strain showed the 
least variation, while the ∆CpsA-∆Acc+ strain expressed the most variation in chain 




Table 1. Maximum, minimum, and average chain length of each sample documented in the chain 
length analysis.  
 
 WT-V ∆-V WT-∆Acc- ∆-∆Acc- WT-∆Acc+ ∆-∆Acc+ 
Maximum 10 20 13 23 23 23 
Minimum 1 1 1 1 1 1 








Figure 18. Images taken for chain length analysis using compound microscopy. A) WT-Vector. B) 
































































































Cell Aggregation Assay 
 Cell aggregation assays were performed according to materials and methods to 
examine the difference in culture growth in WT and ∆CpsA GBS strains. Upon 
examination of culture tubes, WT strains exhibited more turbidity than ∆CpsA strains, 
which exhibited more clearing (Figure 26). Each strain of WT and ∆CpsA GBS were 
compared against one another. In each strain, the ∆CpsA GBS exhibited less turbidity 
than its WT GBS counterpart. One strain, ∆CpsA-∆Acc-, looked similar to WT-∆Acc-, 
which could have likely been due to a disruption of the cell pellet. Although this could be 
an error, the ∆CpsA-∆Acc- strain still exhibited slightly more clearing than the WT-
∆Acc- strain.  




















 An enzyme-linked immunosorbent assay (ELISA) was used to determine capsule 
expression. The amount of alkaline phosphatase (AP) units in each sample is directly 
correlated to the amount of capsule expressed by the cell. The AP units were calculated 
using the following equation:  
𝐴𝑃	𝑈𝑛𝑖𝑡𝑠 =
𝑂𝐷!"#
𝑉𝑜𝑙 ∗ 𝑇 ∗ 𝑂𝐷$""
∗ 1000 
Vol = culture volume in well 
T = time of incubation with substrate 
Figure 26. Comparison of cell aggregation of all six strains created in 
this study. A) WT-Vector. B) WT-∆Acc+. C) WT-∆Acc-. D) ∆CpsA-





ELISA was performed in triplicate in order to determine reproducibility of results. After 
three trials, AP units of each trial were averaged together (Figure 27). Standard error and 
significance values were determined (Figure 27).  
 When comparing WT-Vector and ∆CpsA-Vector strains, ∆CpsA-Vector is not 
able to complement back the same amount of capsule as WT-Vector (Figure 27). 
Calculated p-values suggest that there is significant difference between these strains.  
When comparing the WT-mutant CpsA strains to the WT-Vector, the WT-∆Acc+ 
strain was able to complement back approximately the same amount of capsule as the 
WT-Vector strain, but WT-∆Acc- could not do the same (Figure 27). Calculated p-values 
suggest that there is a significant difference between the WT-Vector and WT-∆Acc- 
strains, but there was no significant difference between WT-Vector and WT-∆Acc+ 
strains (Figure 27). These p-values are consistent with the data shown in Figure 27.  
 When comparing the ∆CpsA-mutant to the ∆CpsA-Vector, both the ∆CpsA-
∆Acc+ and ∆CpsA-∆Acc- strains were able to complement back approximately the same 
amount of capsule as the ∆CpsA-Vector (Figure 27). Calculated p-values suggest that 
there is no significant difference between these strains, and this is consistent with the data 


































Figure 27. Average ELISA data to determine capsule expression. There is a significant 
difference between WT-Vector and WT-∆Acc- strains (p=0.03522) and between WT-∆Acc+ and 
WT-∆Acc- strains (p=0.03607). No significant difference was found between WT-Vector and 
WT-∆Acc+ strains (p=0.9). There is a significant difference between WT-Vector and ∆CpsA-
Vector strains (p=0.0250), but no significant difference between any of the ∆CpsA strains. P-






 S. agalactiae, also known as Group B Streptococcus (GBS), is a commensal 
organism that colonizes the vaginal and genitourinary tract of females, where it can act as 
an opportunistic pathogen in the immunocompromised, such as neonates and fetuses [17]. 
GBS is a widespread pathogen that affects over 22 million pregnant women worldwide, 
with approximately 320 million infant GBS cases as of 2015 [4]. In the United States 
alone, GBS is responsible for approximately 900,000 infections, with a mortality rate of 
6% in neonates and infants [17]. GBS infection is known to be the leading cause of 
neonatal meningitis, and it can also cause other implications, such as septicemia, 
premature birth, and stillbirth [20]. This pathogen can be passed from mother to baby, 
either in utero or during birth, posing a serious threat to neonates and fetuses [17].  
 Because of this threat, pregnant women undergo late gestational screening in 
order to prevent the spread of infection. If the pregnant woman is a colonizer of GBS, 
intrapartum antibiotic prophylaxis (IAP) is administered intravenously during delivery 
[20]. While this treatment is effective at reducing the incidence of GBS infection within 
the first few weeks of life, the long-term effects of antibiotic use in newborns can be 
devastating. A recent study linked antibiotic use in the first two years of life with a higher 
risk of celiac disease, childhood onset asthma, allergic rhinitis, atopic dermatitis, 
overweigh, obesity, and ADHD [2]. Therefore, the need for improved, specific treatment 
for GBS infection in neonates is of the utmost importance.   
 The most important virulence factor of GBS infection is known to be the capsular 




infection. In GBS, capsule is dependent upon the CpsA protein, which is encoded by the 
cpsA gene. This protein acts as one of the transcriptional regulators of the capsule operon 
and is a multifunctional protein containing an intracellular DNA-binding domain, 3 
transmembrane domains, and two extracellular domains, the LytR and accessory domains 
[6]. Crystal structure of the extracellular domains suggests that they fold separately and 
have separate functions [12]. The CpsA protein is highly homologous among 
Streptococcal species, such as S. iniae, S. pneumoniae, and S. suis [6,8]. Previous 
research suggests that the CpsA protein directly aids in the production of capsule and 
thus, the virulence of GBS [7]. Since capsule is required for GBS survival in the 
bloodstream, understanding the mechanisms of dissemination used by GBS to survive in 
tissue environments, such as the vaginal epithelium, is of crucial importance.  
 Prior research performed in the Neely lab compared percent zebrafish survival 
over days post injection of WT and mutant GBS and S. iniae (Figure 3). This data 
demonstrated that the mutant strains were less virulent, reducing the lethality of infection 
by approximately 60%, compared to the WT strains where 100% of zebrafish died after 7 
days post injection. This data suggested that CpsA plays an unknown, but important role 
in virulence of GBS.  
Much of the previous CpsA research has focused on the LytR domain, however 
no previous research has analyzed the effect of a deletion of the accessory domain. The 
goal of this study was to determine the role of the accessory domain on CpsA function 
and capsule production in GBS by deletion of the accessory domain and then analysis of 
the mutated CpsA using a series of virulence assays. The accessory domain was 




coli, and then into GBS. Once the mutant strain was transformed, chain length analysis 
was performed to determine the effect of mutant CpsA on chain length morphology.  
Prior studies have suggested that WT GBS strains express shorter chains of cocci 
compared to ∆CpsA GBS strains, which are known to express longer chains of cocci due 
to decreased capsule expression. In this study, when WT CpsA was expressed on the 
plasmid, chains of cocci were shorter than compared to that of the ∆CpsA strains, on 
average (Table 1). This data is consistent with the findings of the chain length analysis 
performed in this study, however, these results provide new information about chain 
length. Interestingly, there was a difference in chain length between the ∆Acc+ and 
∆Acc- mutant strains expressed on both WT and ∆CpsA plasmids, suggesting that the 
intradomain region has some effect on chain length. No previous research has deleted 
both the accessory domain and intradomain region from CpsA. The intradomain region 
connects the accessory domain and LytR domain and is 180 bp in length (60 amino 
acids). While this is a small fragment of CpsA, the results of the chain length analysis 
suggest that this region could play an important role in GBS virulence. Future studies 
should perform the same chain length analysis on WT-WT and ∆CpsA-WT strains as an 
additional control in order to fully understand the impact of mutant CpsA on chain length 
phenotypes.  
An ELISA was used to determine the difference in capsule presence on the cell 
between each strain in this study. In previous analyses, long chain phenotypes have 
correlated to less capsule expression [7]. This is consistent with the data collected in this 
study, where the ∆CpsA-∆Acc+ and ∆CpsA-∆Acc- strains expressed the longest chains 




the WT-Vector strain looks phenotypically similar to the WT-∆Acc+ and WT-∆Acc- 
strains, even though the capsule expression between the three strains varied significantly. 
All three WT strains expressed similar chain lengths, with approximately 85% of those 
samples being 1-2 cocci per chain. However, the WT strains expressed different capsule 
levels, with WT-V and WT-∆Acc- being statistically significant from one another.  
Based on the ELISA data, the WT-∆Acc- strain showed less capsule than the WT-
Vector strain, even though WT CpsA was expressed from the chromosome. This suggests 
that the WT-∆Acc- strain causes a dominant negative effect because this mutation is 
interfering with the normal function of CpsA (Figure 27). The expression of only the 
LytR domain on both the vector and plasmid in the WT-∆Acc- strain is inhibiting capsule 
expression in some way. The WT-∆Acc+ strain does not cause a dominant negative 
effect, however, because this strain is able to complement back approximately the same 
amount of capsule expressed by the WT-Vector (Figure 27). Furthermore, the difference 
in capsule expression between the WT-∆Acc- and WT-∆Acc+ strains suggests that the 
intradomain region plays an important, but unknown role. This data is interesting, since 
no previous work has studied the effect of the intradomain region on capsule expression 
in GBS CpsA.  
A cell aggregation assay was performed in order to determine the difference in 
bacterial culture suspension between each strain. When comparing all six strains overall, 
the WT GBS strains exhibited more turbidity than the ∆CpsA GBS strains (Figure 26). 
Each WT GBS strain was also compared against its ∆CpsA GBS counterpart (Figure 26). 
In each strain, the WT GBS expressed more turbidity than the ∆CpsA GBS strain. In 




strains. This difference in turbidity and cell pellet size is likely due to the decrease in 
capsule that is caused by the deletion of CpsA. When CpsA is not present, it is 
understood that there is a decrease in capsule and an increase in chain length, which 
causes the cells to be less buoyant and, thus, sink more towards the bottom of the tube, 
causing both a larger cell pellet and less turbidity.  
HHpred is a bioinformatics toolkit that aligns amino acid sequences to determine 
protein homology and predict structure. Previous HHpred data analysis showed no 
protein homologies to the accessory domain of the CpsA protein, until April 2021. The 
most recent data observed via HHpred suggests that the accessory domain has homology 
with substrate binding proteins (Figure 28). These proteins are mostly amino acid binding 
transport proteins, including sensory transduction histidine kinase, periplasmic binding 
transport proteins, glutamate receptors, and ABC transporters (Figure 29) [HHpred]. This 
data suggests that CpsA is homologous to a periplasmic L-aspartate/L-glutamate binding 
protein (DEBP) from Shigella flexneri [HHpred]. Previous data suggests that this protein 
acts as a periplasmic binding protein (PBP) of the ATP-binding cassette (ABC) transport 
system [10]. The PBP aids in transport by trapping the ligand that diffuses through the 
outer membrane into the periplasmic space of bacteria [10]. Further characterization of 
both proteins needs to be performed in order to determine the structural and functional 











Figure 28. A) Alignment of WT CpsA showing homology to other proteins. B) Amino acid alignment 










 While previous studies have deleted the LytR domain of CpsA, none have deleted 
the accessory domain or intradomain region. These studies have suggested that when 
there is a deletion of the LytR domain, significantly less capsule is expressed. This data 
led to the conclusion that the LytR domain is the important in the attachment of capsule 
to the cell wall, acting as a ligase. The accessory domain does, in fact, play a role in 
capsule expression and chain length. The data collected in this study from ELISA data 
suggests that the LytR domain cannot do this alone, and that the accessory domain is also 
required. The accessory domain might be involved in this process initially, by picking up 
the polysaccharide and handing it over to the LytR domain for further attachment. 
Furthermore, the intradomain region might also have a role in capsule attachment to the 
cell wall. The intradomain is important because there are differences between strains that 
express and do not express this region.  
 These conclusions come with some caveats, however. This data has not shown 
that when the protein is expressed from a plasmid that it is actually placed in the 
membrane. Since this study has suggested a dominant negative effect, CpsA most likely 
does make it to the membrane, but further experiments would need to be designed and 
analyzed to monitor the placement of the protein in the membrane. In addition, the ∆Acc- 
strains are missing the 60 amino acid intradomain region which allows the LytR domain 
to be closer to the membrane itself. The WT-∆Acc- strain caused a dominant negative 
effect, suggesting that the LytR domain might not be able to function correctly, without 






There are still many more assays that need to be performed in order to determine 
the role of the accessory domain on CpsA function and capsule production in GBS. These 
experiments include fluorescent vancomycin assays, Western blots, and virulence studies 
using zebrafish as a model organism.  
Fluorescent vancomycin assays can be used to determine the cell wall integrity of 
modified CpsA. In this experiment, newly modified cell walls in the samples are tagged 
with fluorescent vancomycin stain and observed with confocal microscopy. This allows 
for the visualization of defects in the cell wall which could be attributed to mutated 
CpsA. Previous studies have shown that WT CpsA fluoresces just around the outside of 
the cell wall, while ∆CpsA strains can be fully fluorescent. This difference is likely due 
to lower cell wall integrity of ∆CpsA strains, which allows the cell walls to be leaky and 
the stain to enter the entire cell. It is hypothesized that mutations in CpsA will cause a 
decrease in cell wall integrity due to the proposed interactions of CpsA with protein 
components associated with the cell wall.  
A Western blot can be used to confirm if the protein is being displayed on the 
outside of the cell. This allows for the confirmation of whether or not the protein is 
actually making it to the membrane or not. In this experiment, the cell wall and cell 
membrane would be separated from the cytoplasm, resulting in two fractions. An 
antibody to the MBP protein, which is used to tag CpsA, would be used. If the CpsA 
protein is located properly, it would appear in the membrane fraction, but not in the 




Microinjection of zebrafish can be used to visualize the path of infection via 
fluorescently tagged immune cells. This allows for the understanding of the function of 
the accessory domain as a virulence factor of GBS. In these experiments, two types of 
injections would occur. The first is a yolk sac injection, which would cause a systemic 
infection and could be used to measure overall virulence of the strain. The second type of 
injection that would occur is an otic vesicle injection, which would cause a localized 
infection and can be used to determine the chemotaxis of neutrophils to the site of 
infection. Previous research performed in the Neely lab suggests that 100% zebrafish 
succumb to WT GBS infection by 72 hours post injection. The effect of mutant CpsA 
injection can be compared to this data to determine if the mutant strain is more or less 
virulent. It is hypothesized that mutated CpsA will decrease the amount of capsule on the 
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